nChroma Bio
nChroma Bio is a biotechnology company focused on developing in vivo targeted genetic medicines. Their integrated platform combines epigenetic editing with non-viral delivery to address limitations in current genetic medicine approaches, expanding the scope of treatable diseases. Their lead candidate, CRMA-1001, targets chronic hepatitis B and D.
Buy Funded Startups lists
Funding Round:
Funding Amount: $75M
Date: 11-Dec-2024
Investors: Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, Newpath Partners, 5AM Ventures, DCVC Bio, F-Prime Capital, GV (Google Ventures), Janus Henderson Investors, Mubadala Capital, Omega Funds, Sixth Street, Sofinnova Partners, T. Rowe Price, Wellington Management, Alexandria Venture Investments, Casdin Capital, Menlo Ventures, Wilson Sonsini Goodrich & Rosati
Markets: Biotechnology, Genetic Medicine, Epigenetics
HQ: Boston, Massachusetts, United States
Founded: 2024
Website: https://www.nchromabio.com/
LinkedIn: https://www.linkedin.com/company/nchroma-bio
Twitter: https://twitter.com/nchromabio
Crunchbase: https://www.crunchbase.com/organization/nchroma-bio
Leave a Comment
Comments
No comments yet.